• Home
  • About Us
  • Pipeline
  • QMS
  • News
  • Contact Us
  • 中文版
Shanghai Yingli Pharmaceutical Co., Ltd. Shanghai Yingli Pharmaceutical Co., Ltd. Shanghai Yingli Pharmaceutical Co., Ltd. Shanghai Yingli Pharmaceutical Co., Ltd.
  • Home
  • About Us
  • Pipeline
  • QMS
  • News
  • Contact Us
  • 中文版
  • Dedicated to serving unmet medical needs of patients
    Our Mission
  • Innovation foremost, patients first
    Our values
  • We strive to build an internationally recognized innovative pharmaceutical company
    Our Vision
014月
Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3K inhibitor, linperlisib
0 Comments

Linperlisib provides…

1911月
Shanghai Yingli Pharmaceutical Co., Ltd. initiates phase I clinical trial of YL-90148, a selective uric acid reabsorption inhibitor for the treatment of gout and asymptomatic hyperuricemia

Nov. 19, 2018, Shang…

1411月
The phase I clinical trial protocol discussion meeting for Shanghai Yingli Pharmaceutical’s novel immune-oncology agent YL-13027 has been successfully held in Shanghai

Nov. 14, 2018, Shang…

2610月
The phase II clinical trial investigators meeting for Shanghai Yingli Pharmaceutical’s novel anti-cancer agent YY-20394 has been successfully held in Chengdu

Oct. 26, 2018, Shang…

1110月
Shanghai Yingli Pharmaceutical announces FDA Orphan Drug Designation for YY-20394 for both indications (FL and CLL/SLL)

Oct. 11, 2018, Shang…

We strive to build an internationally recognized innovative pharmaceutical company

Contact Us

We're currently offline. Send us an email and we'll get back to you, asap.

Send Message

© 2022 · YL-Pharma Co., Ltd.